LGND News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LG

Mkt Cap

$5.89B

Volume

125.98K

Next Earnings

October 29th

Loading chart

LG

LGNDLigand Pharmaceuticals Inc.

LGND

Pay with—

Available Balance0.00

LG

Mkt Cap

$5.95B

Volume

125.98K

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Ligand to Participate in September Investor ConferencesLigand Pharmaceuticals announced that its senior management team will participate in three upcoming investor conferences in September 2026: Wells Fargo Healthcare Conference (September 8), Citi 2026 Biopharma Back to School Conference (September 10), and H.C. Wainwright 28th Annual Global Investment Conference (September 14). The company will host fireside chats and one-on-one meetings with investors at these events.GlobeNewswire Inc. · Aug 26, 2026

3 Overlooked Stocks Positioned for the Next Market RotationAs tech stocks cool and market concentration risks increase, investors should diversify into overlooked sectors. Healthcare, insurance, and regional banking are quietly building momentum. Three recommended stocks are Ligand Pharmaceuticals (royalty-based biotech model with strong growth projections), Aflac (insurance with 44-year dividend history and pet insurance growth), and Atlantic Union Bankshares (regional bank with stable fundamentals and 3.5% dividend yield).Investing.com · Jul 13, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.The Motley Fool · Jul 6, 2026

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateXOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.Benzinga · Jun 12, 2026

Ligand Announces 2026 Investor Day in New York CityLigand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026, featuring presentations from senior management on the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast will be available through the company's Investor Relations website.GlobeNewswire Inc. · Jun 10, 2026

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 MillionAndrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold 5,000 shares worth approximately $1.14 million on June 1, 2026, through the exercise and immediate disposition of stock options. Post-transaction, Reardon retains 41,382 shares and 39,444 employee stock options. The analyst views this as income supplementation rather than a loss of confidence, noting Ligand's strong 123.61% one-year return and growing royalty revenue (up 56% YoY in Q1), though Captisol sales declined.The Motley Fool · Jun 7, 2026

Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC FilingInvestment fund Villere St Denis J & Co LLC completely exited its position in Euronet Worldwide, selling 244,878 shares worth approximately $17.53 million in Q1 2026. The liquidation represents a full exit from a position that previously comprised 1.9% of the fund's assets under management. Euronet shares have declined 25.4% over the past year, underperforming the S&P 500 significantly.The Motley Fool · May 4, 2026

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law FirmThe Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.GlobeNewswire Inc. · Apr 28, 2026

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 MillionLigand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.Benzinga · Apr 27, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.GlobeNewswire Inc. · Apr 27, 2026

to start trading

LG

LGNDLigand Pharmaceuticals Inc.

LGND

Pay with—

Available Balance0.00

Your PositionYou don't own any LGND yet.

Related Tickers

Earnings